Results 21 to 30 of about 47,221 (287)
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) [PDF]
, 2005 Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC).
Baselga J +9 more
core +1 more source
Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. [PDF]
, 2015 To establish the extent to which systematic reviews and meta-analyses of individual participant data (IPD) are being used to inform the recommendations included in published clinical ...
Cochrane IPD Meta-analysis Methods Group, . +6 more
core +7 more sources
Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer [PDF]
, 2017 Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients.
Cardelli, Patrizia +5 more
core +1 more source
Anthracycline-induced cardiotoxicity and senescence
Frontiers in Aging, 2022 Cancer continues to place a heavy burden on healthcare systems around the world. Although cancer survivorship continues to improve, cardiotoxicity leading to cardiomyopathy and heart failure as a consequence of cancer therapy is rising, and yesterday’s ...
Laura K. Booth +4 more
doaj +1 more source
Cells, 2023 Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, but we cannot predict who may suffer from this complication. CDA is a complex trait with a polygenic component that is mainly unidentified.
Aurora Gómez-Vecino +51 more
doaj +1 more source
Epirubicin. A new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature [PDF]
, 2015 BACKGROUND: Current knowledge indicate that epirubicin administration in late pregnancy is almost devoid of any fetal cardiotoxicity. We report a twin pregnancy complicated by breast cancer in which epirubicin administration was causatively linked to ...
BRUNELLI, Roberto +10 more
core +2 more sources
Biochemistry Research International, 2012 Anthracyclines remain the cornerstone of treatment in many malignancies but these agents have a cumulative dose relationship with cardiotoxicity. Development of cardiomyopathy and congestive heart failure induced by anthracyclines are typically dose ...
David Montaigne +2 more
doaj +1 more source
Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]
, 2003 Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core +1 more source
Interactions of Cisplatin and Daunorubicin at the chromatin level [PDF]
, 2020 Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro.
Bacsó, Zsolt +7 more
core +2 more sources
BJS (British Journal of Surgery), EarlyView., 2020 This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source